Trials / Completed
CompletedNCT05002621
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
Exploratory Investigation of Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observational | Enrolled patients had a prescription for mepolizumab provided during the course of routine clinical care, and enrollment occurred prior to the initiation of mepolizumab. |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2023-02-13
- Completion
- 2025-12-11
- First posted
- 2021-08-12
- Last updated
- 2026-03-18
- Results posted
- 2026-03-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05002621. Inclusion in this directory is not an endorsement.